(Amherst, NH) – One of the bright spots in recent medical science has been the emergence of treatments for chronic diseases. Patients suffering from conditions such as rheumatoid arthritis, multiple sclerosis and Hepatitis C are often able to achieve a higher quality of life using therapeutic drugs that did not exist a short time ago.
The success of these treatments relies on more than recombinant proteins and monoclonal antibodies. For chronic conditions where self-administration is a standard component of the treatment protocol, patient compliance is a major factor in treatment outcomes. To realize a high level of compliance, drug developers and practitioners are turning to sophisticated devices that are developed, approved and marketed in combination with the drug. One of the best examples of the commercial and therapeutic success of this strategy is the current generation pen injector.
Driven by application specific design features and consumer-oriented focus, pen injectors are penetrating the market for injectable drug delivery at the expense of traditional drug delivery methods. Advances in synthetic materials and concurrent development partnerships between pen designers and drug developers are also important factors in the growth of this segment.
Pen injectors are already a leading drug delivery method in Europe where more than half of all diabetics use them to administer insulin injections. In other major therapeutic areas such as the administration of immune modulators for the treatment of autoimmune diseases and Hepatitis C, they have quickly gained market share and become a dominant factor in self-care for millions of patients.
These findings are contained in a new and comprehensive report: Pen Injectors: Devices, Drugs and Disease Therapeutics. The survey concludes that pen injectors will continue to expand as device designers create pen devices that address the specific needs of end users.
More information is available at
http://www.greystoneassociates.org/Pen_Injectors.htm
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
